Organogenesis Holdings Inc (ORGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $105.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Organogenesis Holdings Inc (ORGO) Stock Forecast
Analysts expect Organogenesis Holdings (ORGO) to earn -$1.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $187.82M. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.49.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 24.9%.
- Fiscal year ending Dec 31, 2026
- -$1.37
- EPS consensus, revenue $187.82M
- Fiscal year ending Dec 31, 2027
- -$0.49
- EPS consensus, revenue $234.65M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.37 | -$1.37 to -$1.37 | 1 | $187.82M | $184.30M to $191.35M | 2 |
| Dec 31, 2027 | -$0.49 | -$0.49 to -$0.49 | 1 | $234.65M | $226.70M to $242.60M | 2 |
Quarterly Estimates
The EPS consensus falls from -$0.13 for the quarter ending Dec 31, 2026 to -$0.14 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.13 | -$0.15 to -$0.12 | 4 | $62.63M | $56.74M to $68.14M | 4 |
| Mar 31, 2027 | -$0.14 | -$0.14 to -$0.14 | 1 | $52.35M | $48.90M to $55.80M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.38.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.37 | -$1.38 | -$1.38 | -$1.38 | -$1.38 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.49 | -$0.31 | -$0.31 | -$0.31 | -$0.31 | N/A |
| Quarter ending Mar 31, 2027 | -$0.14 | -$0.08 | -$0.08 | -$0.08 | -$0.08 | N/A |
Frequently Asked Questions About ORGO
What is the ORGO stock forecast?
Consensus analyst estimates put Organogenesis Holdings's EPS at -$1.37 for the fiscal year ending Dec 31, 2026, on revenue of $187.82M.
What EPS do analysts expect from ORGO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.37, with estimates from -$1.37 to -$1.37 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.49, with estimates from -$0.49 to -$0.49 from 1 analyst.
What revenue do analysts expect from Organogenesis Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $187.82M, with estimates from $184.30M to $191.35M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $234.65M, with estimates from $226.70M to $242.60M.
How many analysts cover ORGO?
1 analyst estimates EPS for Organogenesis Holdings for the fiscal year ending Dec 31, 2026.
ORGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts